Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.

Lu, Chieh-Hsiang; Yang, Chen-Yi; Li, Chung-Yi; Hsieh, Cheng-Yang; Ou, Huang-Tz

Lu, Chieh-Hsiang; Yang, Chen-Yi; Li, Chung-Yi; Hsieh, Cheng-Yang; Ou, Huang-Tz.

Afiliação

Lu CH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan.
Yang CY; College of Chinese Medicine, China Medical University, Taichung, Taiwan.
Li CY; Department of Biotechnology, Asia University, Taichung, Taiwan.
Hsieh CY; Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 7010, Taiwan.
Ou HT; Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Diabetologia ; 61(3): 562-573, 2018 03.

Article em En | MEDLINE | ID: mdl-29138876

Assuntos

Demência/prevenção & controle; Diabetes Mellitus Tipo 2/tratamento farmacológico; Diabetes Mellitus Tipo 2/fisiopatologia; Hipoglicemiantes/uso terapêutico; Metformina/uso terapêutico; Tiazóis/uso terapêutico; Tiazolidinedionas/uso terapêutico; Idoso; Demência/fisiopatologia; Combinação de Medicamentos; Feminino; Humanos; Estudos Longitudinais; Masculino; Pioglitazona

Palavras-chave

Dementia; Glucose-lowering drugs; Pioglitazone; Type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiazóis / Demência / Tiazolidinedionas / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Metformina Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google